
Voting Apple’s 2023 Proxy
On Wednesday, 1/24, the corporate governance team consisting of DJ Jun, Rathika Nair and Michael Rocco O’Krepky presented their recommendations for how the fund should vote our $80K worth of Apple shares in the upcoming shareholder meeting. The motivation was that being responsible owners of our assets means participating in the governance of the companies…
Read MoreMove cash to SGOV
What is SGOV? SGOV is iShares 0-3 Month Treasury ETF (SGOV). It invests in ultra-short-term treasuries, is passively managed, has a low expense ratio of 0.07%, and has an average bond duration of 0.09 years. What is the investment thesis? At the time of this writing (December 2023), cash represents more than 16% of…
Read MoreBuy PAVE – ETF Sector Pitch
What is PAVE? PAVE is Global X U.S. Infrastructure Development ETF which “seeks to invest in companies that stand to benefit from a potential increase in infrastructure activity in the United States.” Why infrastructure? What is the investment thesis? We believe that the market currently underestimates the need for infrastructure investments and the magnitude…
Read MoreUtilities Sector Thesis
The utilities sector is one of the main sectors of the economy and is made up of companies such as electric, gas, and water utility firms. Utility stocks are generally not high growth stocks that will outperform the market, but rather high yielding equity investments. These companies require significant infrastructure and therefore often carry large…
Read MoreBuy Spotify
Spotify is a music streaming platform developed by Swedish company Spotify AB, headquartered in Stockholm, Sweden and listed on the NYSE as of April 2018. Spotify is an attractive investment for a multitude of reasons. For the first time in 15 years, Apple cut its revenue guidance by $5 billion due to a downturn of…
Read MoreSell Facebook Thesis
The SIF currently owns 75 shares of Facebook (FB) and it makes up 2% of the portfolio. Although the company has grown its profitability and has a relatively low beta of .62 over the past 3 months, the ongoing concerns over data collection, privacy issues, personnel conflicts, and Russian interference pose sufficient risk to warrant selling out…
Read MoreGilead Pitch
Gilead Pharmaceuticals, a biopharmaceutical company, discovers, develops and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. Gilead pharmaceuticals is an attractive investment for three main reasons. First, it is incredibly undervalued compared to its competition. Gilead’s EV/EBITDA ratio is 8.18 currently compared to an industry average of…
Read More- 2 of 2
- « Previous
- 1
- 2